Product Description
LIDOCAINE (LYE doe kane) is an anesthetic. It causes loss of feeling in the skin and surrounding tissues. It is used to prevent and to treat pain from some procedures. This medicine is also used to treat minor burns, scrapes and insect bites. (Sourced from: https://my.clevelandclinic.org/health/drugs/19854-lidocaine-skin-cream-or-ointment)
Mechanisms of Action: Sodium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Topical, Transdermal
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: ZARS Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, China, Czech Republic, France, Germany, Italy, Japan, Netherlands, Norway, Spain, United Kingdom, United States
Active Clinical Trial Count: 38
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Anesthesia Related|Cesarean Section|Collagen Diseases|DiGeorge Syndrome|Facial Nerve Diseases|Facial Pain|Injuries/wounds Unspecified|Intervertebral Disc Degeneration|Intestinal Diseases|Low Back Pain|Neuralgia, Postherpetic|Neuromyelitis Optica|Neuropathic Pain|Other|Pain Unspecified|Premature Ejaculation
Phase 2: Abdominal Pain|Anorexia|Chronic Pain|Hearing Loss, Bilateral|Ileus|Pelvic Pain
Phase 1: Diabetic Foot|Glaucoma|Idiopathic Pulmonary Fibrosis|Lung Diseases, Interstitial|Progressive Pulmonary Fibrosis|Skin Ulcer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12624000785505 |
ACTRN12624000785505 | P1 |
Not yet recruiting |
Glaucoma |
2025-10-01 |
2024-09-07 |
Treatments |
|
CTR20252515 |
CTR20252515 | P1 |
Completed |
Premature Ejaculation |
2025-09-09 |
2025-10-05 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT05921292 |
OM-CTP-002 | P1 |
Completed |
Skin Ulcer |
2024-01-22 |
2024-06-28 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT05417425 |
OM-CTP-003.1 | P1 |
Completed |
Diabetic Foot |
2023-10-31 |
2024-06-07 |
Primary Endpoints |
|
ACTRN12620001141932p |
SPPH | P1 |
Not yet recruiting |
Progressive Pulmonary Fibrosis|Lung Diseases, Interstitial|Idiopathic Pulmonary Fibrosis |
2021-01-22 |
|||
2021-006632-67 |
QETAL | P3 |
Active, not recruiting |
Anesthesia Related|Cesarean Section |
2023-09-08 |
|||
NCT05793892 |
CU-30101-304 | P3 |
Completed |
Anesthesia Related|Facial Pain|Collagen Diseases|Facial Nerve Diseases |
2023-08-23 |
30% |
2024-11-13 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
NCT03737461 |
RESPINE | P3 |
Active, not recruiting |
Low Back Pain|Intervertebral Disc Degeneration |
2022-05-30 |
10% |
2023-08-15 |
|
2015-002160-17 |
2015-002160-17 | P3 |
Active, not recruiting |
Injuries/wounds Unspecified|Pain Unspecified |
2017-12-24 |
2022-03-13 |
Treatments |
|
2023-504466-28-00 |
SENS-501-101 | P2 |
Recruiting |
Hearing Loss, Bilateral |
2030-12-31 |
2025-05-02 |
Treatments |
|
NCT05923086 |
ORE001PIIPOI | P2 |
Recruiting |
Ileus |
2025-12-31 |
35% |
2024-10-04 |
Primary Completion Date|Primary Endpoints |
NCT05707208 |
ST-CP-202 | P2 |
Recruiting |
Chronic Pain |
2025-08-01 |
2% |
2025-05-17 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
2024-516958-22-00 |
OREPhIIElderly | P2 |
Recruiting |
Other |
2025-07-30 |
2025-05-02 |
Treatments |
|
2023-510499-30-00 |
OREPhIIAnorexia | P2 |
Not yet recruiting |
Anorexia |
2025-06-30 |
2025-05-02 |
Treatments |
|
2023-508224-35-01 |
2023-508224-35-01 | P2 |
Recruiting |
Abdominal Pain|Chronic Pain |
2025-03-31 |
2025-05-02 |
Treatments |
|
ACTRN12621000589886 |
ACTRN12621000589886 | P2 |
Recruiting |
Chronic Pain|Pelvic Pain |
2023-12-29 |
2024-08-29 |
Treatments |
|
NCT07076641 |
LIDORACHI | P3 |
Not yet recruiting |
Intestinal Diseases |
2027-07-30 |
11% |
2025-07-23 |
Primary Endpoints|Treatments |
NCT07032597 |
M21-782 | P3 |
Active, not recruiting |
DiGeorge Syndrome |
2026-08-01 |
19% |
2025-08-15 |
Primary Completion Date|Primary Endpoints|Treatments|Trial Status |
jRCT2031240211 |
jRCT2031240211 | P3 |
Recruiting |
Neuralgia, Postherpetic |
2025-06-30 |
|||
NCT05452070 |
M21-784 | P3 |
Completed |
Neuromyelitis Optica |
2025-05-08 |
7% |
2025-05-15 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
CTR20212038 |
CTR20212038 | P3 |
Completed |
Neuropathic Pain |
2023-11-30 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20252536 |
CTR20252536 | P1 |
Completed |
Premature Ejaculation |
2025-08-06 |
2025-09-07 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20252516 |
CTR20252516 | P1 |
Completed |
Premature Ejaculation |
2025-08-05 |
2025-10-21 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
2023-507633-21-00 |
MN45053 | P3 |
Withdrawn |
Unknown |
2029-07-31 |
2025-05-02 |
Treatments |
|
ACTRN12625001044415 |
ACTRN12625001044415 | P3 |
Not yet recruiting |
Neuralgia, Postherpetic |
2027-09-30 |
2025-09-23 |
Treatments |